Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9Y2H9

UPID:
MAST1_HUMAN

ALTERNATIVE NAMES:
Syntrophin-associated serine/threonine-protein kinase

ALTERNATIVE UPACC:
Q9Y2H9; O00114; Q8N6X0

BACKGROUND:
The Microtubule-associated serine/threonine-protein kinase 1, alternatively known as Syntrophin-associated serine/threonine-protein kinase, is crucial for brain development. It ensures the correct assembly of microtubule filaments, interfacing with the dystrophin/utrophin network through syntrophins. The phosphorylation states of DMD or UTRN adjust their binding to associated proteins, highlighting its regulatory significance.

THERAPEUTIC SIGNIFICANCE:
Implicated in the pathogenesis of Mega-corpus-callosum syndrome with cerebellar hypoplasia and cortical malformations, this protein's dysfunction leads to severe neurodevelopmental issues. Exploring the function of Microtubule-associated serine/threonine-protein kinase 1 offers a promising avenue for developing targeted therapies for this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.